Karina Leksy, Grzegorz Gawron, Rafaela Rosário
Associations between Polish school principals' health literacy and implementation of the Health Promoting School approach during the COVID-19 pandemic
PloS one
androgen receptor pathway inhibitors arpis widely prescribed metastatic castrationresistant prostate cancer mcrpc realworld frequencies potential impacts comorbidities concomitant medication conmed interactions arpis well described patients receiving arpis mcrpc identified electronic prostate cancer australian database epad demographics clinicopathologic characteristics outcome data extracted conmeds comorbidities collected medical records potential interacting comorbidities defined trial posttrial data clinically significant drugdrug interactions ddis identified using uptodate lexicomp stockleys databases patient characteristics comorbidity interactions ddis outcomes analyzed two hundred thirtyfive patients received first secondline arpis mcrpc 2012 2021 median followup 27 months one hundred sixteen received abiraterone acetate aap 135 received enzalutamide enz median age 74 years median number conmeds 4 clinically significant ddis occurred 55 47 aap patients 90 67 enz patients 5 ddis predicted affect arpi pharmacokinetics pk pharmacodynamics whereas 95 predicted impact conmed pk increase toxicity risk patients receiving enz ddis associated lower psa50 50 v 74 p 04 poorer overall survival 28 v 45 months p 04 although statistical significance maintained multivariate analysis significant survival differences seen ddis patients receiving aap potential interactions comorbidities arpi present 72 aap 14 enz significant associated survival differences ddis drugcomorbidity interactions realworld patients receiving arpis mcrpc common may affect outcomes ongoing clinician education regarding ddis necessary optimize patient outcomes